Subject
Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine
Reference28 articles.
1. U.S. Food and Drug Administration. PIFELTRO (doravirine) prescribing information, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210806s003lbl.pdf; 2019 [accessed 09 August 2022].
2. European Medicines Agency. Pifeltro product information, Annex I – Summary of product characteristics, https://www.ema.europa.eu/en/documents/product-information/pifeltro-epar-product-information_en.pdf; 2022 [accessed 09 August 2022].
3. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial;Molina;Lancet HIV,2020
4. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial
5. Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial;Kumar;J Acquir Immune Defic Syndr,2021
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献